Product Details
| Product Name:
Losigamone |
CAS No.:
112856-44-7 |
| Purity:
100% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Losigamone |
| Description | Losigamone (AO-33), an agonist of the GABA receptor, can be utilized in studies on the treatment of partial seizures. |
| In vivo | Losigamone (AO-33) was tested in 52 healthy male volunteers in 4 placebo-controlled phase I studies. In the study 1 single dose of 100, 200, 300, 500, 700, and 1,000 mg losigamone was given as a fast-releasing capsule to 12 subjects. The pharmacokinetics of losigamone measured after administration of 100, 300, and 700 mg was linear. Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h. In study, 2,500 mg losigamone was given as a fast-release capsule for 6 days (t.i.d.) to 12 subjects. There was a small but statistically significant decrease for the AUC but no change in t1/2, Cmax, or tmax comparing single dose kinetics on days 1 and 8. There appeared to be no change in caffeine clearance on days 1 and 9. Study 2 was repeated in 20 volunteers with a film-coated tablet. Pharmacokinetic parameters appeared to be unaffected by this change in galenical formulation. In the study 4 daily doses of 400, 1,200, and 1,800 mg losigamone were given 28 days to 24 subjects. The kinetics of caffeine and antipyrine were compared on days 1 and 29. With the exception of t1/2 for antipyrine in the 400 mg group there was no statistically significant change in pharmacokinetic parameters. Generally, losigamone was well tolerated and no serious adverse side effects occurred. In some subjects, a reversible increase in transaminases was observed.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | ADD137022 | Losigamone |
| Inhibitors Related | Valproic acid sodium salt | DL-Menthol | Penicillin G sodium salt | Valproic Acid | Halothane | Chlorothymol | Piperazine citrate | Riluzole | Gabapentin | (-)-α-Pinene |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:176975-26-1
$160.00 / 1mg
-
CAS:122110-53-6
$166.00 / 500mg
-
CAS:2014343-04-3
$372.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States